AbbVie Stock News

If I had to invest $100K today in Dividend Aristocrats, here's what I would do. I'd spread my investments in between my top 10 picks within the list. I show you what portfolio profile this would create, and where it falls short.

AbbVie continues to navigate Humira's LOE brilliantly, with the higher rebates and lower pricing ensuring its market-leading share despite the notable impacts on the top/bottom lines. The management has also raised their FY2024 guidance despite the multiple adjustments related to the acquired IPR&D and milestones expenses. These developments underscore ABBV's robust ex-Humira portfolio growth a...

AbbVie on Wednesday lowered its 2024 adjusted profit forecast as the drugmaker expects to incur $937 million in acquisition-related expenses.

In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.

In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.

Just 1% of all stocks listed on the major U.S. exchanges are Dividend Aristocrats. These are the 67 companies listed on the S&P 500 that have raised their dividends for 25 consecutive years or more.

NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens.

One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.